Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Intrinsic Value
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. [ Read More ]
The intrinsic value of one AMPH stock under the Base Case scenario is 61.57 USD. Compared to the current market price of 43.91 USD, Amphastar Pharmaceuticals Inc is Undervalued by 29%.
Valuation Backtest
Amphastar Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling AMPH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Amphastar Pharmaceuticals Inc
Current Assets | 489.6m |
Cash & Short-Term Investments | 256.8m |
Receivables | 115.5m |
Other Current Assets | 117.3m |
Non-Current Assets | 1B |
Long-Term Investments | 15.2m |
PP&E | 315.6m |
Intangibles | 613.3m |
Other Non-Current Assets | 79.2m |
Current Liabilities | 225.4m |
Accounts Payable | 25.4m |
Accrued Liabilities | 197.9m |
Other Current Liabilities | 2m |
Non-Current Liabilities | 648.1m |
Long-Term Debt | 589.6m |
Other Non-Current Liabilities | 58.5m |
Earnings Waterfall
Amphastar Pharmaceuticals Inc
Revenue
|
644.4m
USD
|
Cost of Revenue
|
-290.6m
USD
|
Gross Profit
|
353.8m
USD
|
Operating Expenses
|
-154.1m
USD
|
Operating Income
|
199.7m
USD
|
Other Expenses
|
-62.1m
USD
|
Net Income
|
137.5m
USD
|
Free Cash Flow Analysis
Amphastar Pharmaceuticals Inc
What is Free Cash Flow?
AMPH Profitability Score
Profitability Due Diligence
Amphastar Pharmaceuticals Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Amphastar Pharmaceuticals Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
AMPH Solvency Score
Solvency Due Diligence
Amphastar Pharmaceuticals Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Amphastar Pharmaceuticals Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMPH Price Targets Summary
Amphastar Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for AMPH is 67.32 USD with a low forecast of 61.61 USD and a high forecast of 74.55 USD.
Ownership
AMPH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AMPH Price
Amphastar Pharmaceuticals Inc
Average Annual Return | 8.9% |
Standard Deviation of Annual Returns | 12.03% |
Max Drawdown | -45% |
Market Capitalization | 2.1B USD |
Shares Outstanding | 48 095 900 |
Percentage of Shares Shorted | 12.22% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. The company is headquartered in Rancho Cucamonga, California and currently employs 1,761 full-time employees. The company went IPO on 2014-06-25. The firm is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. Its segments include Finished pharmaceutical products and API products. The Finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Glucagon for injection emergency kit is indicated for the treatment of severe hypoglycemia.
Contact
IPO
Employees
Officers
The intrinsic value of one AMPH stock under the Base Case scenario is 61.57 USD.
Compared to the current market price of 43.91 USD, Amphastar Pharmaceuticals Inc is Undervalued by 29%.